{"name":"TARGET","title":"","children":[{"id":"AHR","name":"AHR","presenterLast":"AHR","children":[{"id":3150,"name":3150,"title":"Small-molecule antagonists of the Aryl Hydrocarbon Receptor (AhR) promote activation of human PBMCs in vitro and demonstrate significant impact on tumor growth and immune modulation in vivo","presenterFirst":"Fred","presenterLast":"Aswad","keywords":"Aryl hydrocarbon receptor;Immunomodulation;Small molecule inhibitor;Drug discovery","target":"AHR","tumor":"colorectal","sage":"discovery","pharma":"pharma","combo":"no","model":"preclinical xeno"},{"id":7608,"name":7608,"title":"Targeting the IDO and TDO pathway through inhibition of the aryl hydrocarbon receptor","presenterFirst":"Jeremy","presenterLast":"Tchaicha","keywords":"Aryl hydrocarbon receptor;Immunotherapy;Tumor microenvironment","target":"AHR","tumor":"melanoma_colorectal","sage":"discovery","pharma":"pharma","combo":"yes","model":"preclinical xeno"}]},{"id":"arginase1","name":"arginase1","presenterLast":"arginase1","children":[{"id":2320,"name":2320,"title":"Depletion of blood arginine with pegzilarginase (AEB1102) in combination with anti-PD-L1 increases tumor infiltration by immune cells and enhances antitumor activity","presenterFirst":"Giulia","presenterLast":"Agnello","keywords":"Arginine deprivation;Tumor microenvironment;Metabolism;Checkpoint inhibitors","target":"arginase1","tumor":"colorectal","sage":"discovery","pharma":"pharma","combo":"yes","model":"preclinical xeno"},{"id":6200,"name":6200,"title":"High-throughput fluorescence-based assay for screening of Arginase I inhibitors for cancer immunotherapy","presenterFirst":"Yvonne","presenterLast":"Grobben","keywords":"Immunotherapy;Structure-based drug design;High throughput assay;Arginase","target":"arginase1","tumor":"NA","sage":"drug","pharma":"pharma","combo":"no","model":"preclinical in vitro"}]},{"id":"CCR2/5","name":"CCR2/5","presenterLast":"CCR2/5","children":[{"id":3522,"name":3522,"title":"Preclinical antitumor activity of a CC chemokine receptor (CCR) 2/5 dual antagonist as monotherapy and in combination with immune checkpoint blockade","presenterFirst":"Qihong","presenterLast":"Zhao","keywords":"Chemokine receptor;Immunosuppression;CCR2/5;Tumor-associated myeloid and T cells","target":"CCR2/5","tumor":"colorectal_breast","sage":"target-tumor","pharma":"pharma","combo":"yes","model":"preclinical xeno"},{"id":7423,"name":7423,"title":"Inhibition of chemokine receptor 2 (CCR2) with a small molecule antagonist enhances the effectiveness of checkpoint inhibition by altering the tumor microenvironment in mouse colorectal tumors: Reducing tumor size and increasing long term survival","presenterFirst":"James","presenterLast":"Campbell","keywords":"Chemokine receptor;Colorectal cancer;Checkpoint;Gastrointestinal cancers: colorectal","target":"CCR2/5","tumor":"colorectal","sage":"target-tumor","pharma":"pharma","combo":"yes","model":"preclinical xeno"}]},{"id":"CCR4","name":"CCR4","presenterLast":"CCR4","children":[{"id":7441,"name":7441,"title":"EBV associated tumors have increased regulatory T cell recruitment and are therefore a potential indication for treatment with potent and selective small molecule CCR4 antagonists","presenterFirst":"Oezcan","presenterLast":"Talay","keywords":"Epstein-Barr virus;Chemokines;Regulatory T cells","target":"CCR4","tumor":"gastric_headneck_lymphoma","sage":"discovery","pharma":"pharma","combo":"yes","model":"preclinical xeno"}]},{"id":"CD137","name":"CD137","presenterLast":"CD137","children":[{"id":7006,"name":7006,"title":"Small synthetic, multivalent bicyclic peptides that activate T cell costimulatory protein CD137","presenterFirst":"Peter","presenterLast":"Park","keywords":"Immunotherapy;Co-stimulation;Cancer therapy;Targeted therapy","target":"CD137","tumor":"NA","sage":"drug","pharma":"pharma","combo":"no","model":"preclinical in vitro"}]},{"id":"CD47_SIRP","name":"CD47_SIRP","presenterLast":"CD47_SIRP","children":[{"id":3759,"name":3759,"title":"Combination efficacy and safety profile of an orally bioavailable small molecule agent targeting CD47/SIRP\u03b1 axis","presenterFirst":"Murali","presenterLast":"Ramachandra","keywords":"Immunotherapy;Small molecule drugs;Macrophages;Innate immunity","target":"CD47_SIRP","tumor":"colorectal_lymphoma","sage":"target-tumor","pharma":"pharma","combo":"yes","model":"preclinical xeno"}]},{"id":"CSF1-R","name":"CSF1-R","presenterLast":"CSF1-R","children":[{"id":3732,"name":3732,"title":"NMS-P088, a FLT3-KIT-CSF-1R inhibitor with activity on FLT3 F691L as a novel agent in AML","presenterFirst":"Marina","presenterLast":"Ciomei","keywords":"Leukemias: acute myeloid;FLT3;CSF-1R;NMS-P088","target":"CSF1-R","tumor":"NA","sage":"discovery","pharma":"pharma","combo":"no","model":"preclinical xeno"}]},{"id":"CXCR4","name":"CXCR4","presenterLast":"CXCR4","children":[{"id":5311,"name":5311,"title":"CXCR4 inhibition modulates tumor microenvironment and robustly inhibits growth of B16-OVA melanoma","presenterFirst":"James","presenterLast":"Mier","keywords":"CXCR4;T cell;melanoma","target":"CXCR4","tumor":"melanoma","sage":"target-tumor","pharma":"pharma","combo":"yes","model":"preclinical xeno"}]},{"id":"ENPP1","name":"ENPP1","presenterLast":"ENPP1","children":[{"id":8167,"name":8167,"title":"Discovery of ENPP1 inhibitors as agonists of STING pathway","presenterFirst":"Sunil","presenterLast":"Sharma","keywords":"Immunomodulation;Therapeutics;Small molecule inhibitor;Cancer immunotherapy","target":"ENPP1","tumor":"NA","sage":"drug","pharma":"pharma","combo":"no","model":"preclinical in vitro"}]},{"id":"Eselectin_CXCR4","name":"Eselectin_CXCR4","presenterLast":"Eselectin_CXCR4","children":[{"id":5435,"name":5435,"title":"Mobilization of tumor-primed, marrow-infiltrating lymphocytes into peripheral blood with inhibitors of E-selectin or E-selectin and CXCR4","presenterFirst":"William","presenterLast":"Fogler","keywords":"E-selectin;CXCR4;T lymphocytes;Bone marrow","target":"Eselectin_CXCR4","tumor":"colorectal","sage":"drug","pharma":"pharma","combo":"no","model":"preclinical xeno"},{"id":6334,"name":6334,"title":"Dual E-selectin and CXCR4 inhibition reduces tumor growth and metastatic progression in an orthotopic model of osteosarcoma","presenterFirst":"Wei","presenterLast":"Ju","keywords":"E-selectin;CXCR4;Osteosarcoma","target":"Eselectin_CXCR4","tumor":"sarcoma","sage":"target-tumor","pharma":"pharma","combo":"No","model":"preclinical xeno"}]},{"id":"Foxp3","name":"Foxp3","presenterLast":"Foxp3","children":[{"id":2858,"name":2858,"title":"High-affinity antisense oligonucleotides targeting Foxp3 inhibit immunosuppressive function of regulatory T-cells and produce antitumor effects in syngeneic tumor models","presenterFirst":"Charles","presenterLast":"Sinclair","keywords":"Regulatory T cells;Foxp3;Antisense oligonucleotides","target":"Foxp3","tumor":"NA","sage":"drug","pharma":"pharma","combo":"no","model":"preclinical in vitro"}]},{"id":"HDAC","name":"HDAC","presenterLast":"HDAC","children":[{"id":6343,"name":6343,"title":"4SC-202 increases immunogenicity of tumor cells, induces infiltration of tumor microenvironment with cytotoxic T cells, and primes tumors for combinations with different cancer immunotherapy approaches","presenterFirst":"Svetlana","presenterLast":"Hamm","keywords":"Histone deacetylase inhibitor;Combination therapy;Checkpoint","target":"HDAC","tumor":"colorectal","sage":"target-tumor","pharma":"pharma","combo":"yes","model":"preclinical xeno"}]},{"id":"HDAC11","name":"HDAC11","presenterLast":"HDAC11","children":[{"id":2933,"name":2933,"title":"HDAC11 function as a transcriptional regulator in immature myeloid cells to myeloid-derived suppressor cells transition","presenterFirst":"Jie","presenterLast":"Chen","keywords":"Histone deacetylase;MDSCs;C/EBPbeta","target":"HDAC11","tumor":"NA","sage":"discovery","pharma":"pharma","combo":"no","model":"preclinical xeno"}]},{"id":"HSP90","name":"HSP90","presenterLast":"HSP90","children":[{"id":4840,"name":4840,"title":"Transcriptomics analysis of SNX-2112 on immune and mitochodrial genes","presenterFirst":"Everardus","presenterLast":"Orlemans","keywords":"Immune response;SNX-2112;epigenetic Hsp90 inhibitor;oncometabolism","target":"HSP90","tumor":"melanoma_leukemia","sage":"discovery","pharma":"pharma","combo":"no","model":"in silico"}]},{"id":"IAP","name":"IAP","presenterLast":"IAP","children":[{"id":3846,"name":3846,"title":"Smac mimetics APG-1387 synergizes with immune checkpoint inhibitors in preclinical models","presenterFirst":"Yifan","presenterLast":"Zhai","keywords":"IAP;Checkpoint;Immunotherapy","target":"IAP","tumor":"NA","sage":"drug","pharma":"pharma","combo":"yes","model":"preclinical xeno"}]},{"id":"IDO1","name":"IDO1","presenterLast":"IDO1","children":[{"id":2017,"name":2017,"title":"Discovery of DN-016: A highly potent, selective and orally available IDO1 inhibitor for treating cancers","presenterFirst":"Shoujun","presenterLast":"Chen","keywords":"Immunotherapy;IDO1 inhibitor;Immuno-oncology;PD-1 inhibitor","target":"IDO1","tumor":"NA","sage":"drug","pharma":"pharma","combo":"no","model":"preclinical in vitro"},{"id":4503,"name":4503,"title":"Impact of IDO inhibitor on tryptophan and kynurenine pathway reflected in the tumor microenvironment and highlighted using quantitative mass spectrometry imaging","presenterFirst":"Lauranne","presenterLast":"Poncelet","keywords":"Mass spectrometry;Mass spectrometry;Drug delivery","target":"IDO1","tumor":"colorectal","sage":"target-tumor","pharma":"pharma","combo":"no","model":"preclinical xeno"},{"id":5745,"name":5745,"title":"Preclinical evaluation of TQBWX220, a small-molecule inhibitor of IDO1","presenterFirst":"Shilan","presenterLast":"Liu","keywords":"Immunotherapy;Tumor immunity;Tumor microenvironment;IDO1 inhibitor","target":"IDO1","tumor":"colorectal","sage":"drug","pharma":"pharma","combo":"no","model":"preclinical xeno"},{"id":6433,"name":6433,"title":"Identification and characterization of the IDO1 inhibitor LY3381916","presenterFirst":"Frank","presenterLast":"Dorsey","keywords":"Immunomodulation;Small molecule inhibitor;Immunotherapy;Lung cancer","target":"IDO1","tumor":"NA","sage":"drug","pharma":"pharma","combo":"yes","model":"preclinical xeno"},{"id":8314,"name":8314,"title":"T-cell activation through the inhibition of tumor-expressed IDO1 activity in tryptophan metabolism pathway","presenterFirst":"Frank","presenterLast":"Xing","keywords":"T cell;IDO1","target":"IDO1","tumor":"NA","sage":"discovery","pharma":"pharma","combo":"yes","model":"preclinical xeno"}]},{"id":"IDO1_IDO2","name":"IDO1_IDO2","presenterLast":"IDO1_IDO2","children":[{"id":5335,"name":5335,"title":"Indoximod modulates AhR-driven transcription of genes that control immune function","presenterFirst":"Erik","presenterLast":"Brincks","keywords":"Immunotherapy;Aryl hydrocarbon receptor;Immunomodulation","target":"IDO1_IDO2","tumor":"NA","sage":"discovery","pharma":"pharma","combo":"no","model":"preclinical xeno"}]},{"id":"IDO1_TD2","name":"IDO1_TD2","presenterLast":"IDO1_TD2","children":[{"id":2562,"name":2562,"title":"EPL-1410, a novel fused heterocycle based orally active dual inhibitor of IDO1/TDO2, as a potential immune-oncology therapeutic","presenterFirst":"Srinivas","presenterLast":"Gullapalli","keywords":"Cancer immunotherapy;Checkpoint;Tumor microenvironment;Drug discovery","target":"IDO1_TD2","tumor":"colorectal_melanoma","sage":"drug","pharma":"pharma","combo":"yes","model":"preclinical xeno"}]},{"id":"KYN","name":"KYN","presenterLast":"KYN","children":[{"id":5170,"name":5170,"title":"Metabolic modulation of the tumor microenvironment using Synthetic Biotic\u2122 Medicines","presenterFirst":"Kip","presenterLast":"West","keywords":"Immunotherapy;Immunomodulation;Tumor microenvironment;Bacterial treatment","target":"KYN","tumor":"colorectal","sage":"drug","pharma":"pharma","combo":"yes","model":"preclinical xeno"},{"id":7442,"name":7442,"title":"Targeting the IDO/TDO pathway through degradation of the immunosuppressive metabolite kynurenine","presenterFirst":"Xiaoyan","presenterLast":"Zhang","keywords":"Immunotherapy;Tumor microenvironment","target":"KYN","tumor":"NA","sage":"drug","pharma":"pharma","combo":"yes","model":"preclinical xeno"}]},{"id":"LSD1_HDAC","name":"LSD1_HDAC","presenterLast":"LSD1_HDAC","children":[{"id":4634,"name":4634,"title":"Novel, first-in-class dual inhibitors of lysine specific demethylase 1 (LSD1) and histone deacetylatse 1 (HDAC) for treatment of cancer","presenterFirst":"Dhanalakshmi","presenterLast":"Sivanandhan","keywords":"Small molecule inhibitor;Epigenetics","target":"LSD1_HDAC","tumor":"colorectal","sage":"drug","pharma":"pharma","combo":"yes","model":"preclinical xeno"}]},{"id":"MAPK_TLR","name":"MAPK_TLR","presenterLast":"MAPK_TLR","children":[{"id":7250,"name":7250,"title":"MPL-5821, a macrophage targeted ESM<sup>TM</sup> p38 MAPK inhibitor, inhibits the production of TLR agonist induced IL-10 whilst sparing T-cell functionality","presenterFirst":"David","presenterLast":"Moffat","keywords":"Macrophages;MAP kinase;Immune response;Interleukin-10","target":"MAPK_TLR","tumor":"ovarian","sage":"target-tumor","pharma":"pharma","combo":"yes","model":"preclinical xeno"}]},{"id":"MNK1/2","name":"MNK1/2","presenterLast":"MNK1/2","children":[{"id":5676,"name":5676,"title":"eFT508, a potent and highly selective inhibitor of MNK1 and MNK2, regulates T-cell differentiation promoting an antitumor immune response","presenterFirst":"Rajesh","presenterLast":"Sharma","keywords":"Immunotherapy;MNK1/2;T cell differentiation;Antitumor activity","target":"MNK1/2","tumor":"NA","sage":"drug","pharma":"pharma","combo":"no","model":"preclinical xeno"},{"id":5685,"name":5685,"title":"Inhibition of MNK by eFT508 reprograms T-cell signaling to promote an antitumor immune response","presenterFirst":"Craig","presenterLast":"Stumpf","keywords":"Immunomodulation;T cell;MNK;eFT508","target":"MNK1/2","tumor":"NA","sage":"discovery","pharma":"pharma","combo":"no","model":"preclinical xeno"}]},{"id":"PAMP","name":"PAMP","presenterLast":"PAMP","children":[{"id":7521,"name":7521,"title":"Imprime PGG, a soluble yeast b-glucan PAMP, enhancement of anti-tumor responses in combination with tumor targeting antibody is highly dependent on NK cell killing","presenterFirst":"Kathryn","presenterLast":"Fraser","keywords":"Natural killer cells;Immunotherapy;Antibody","target":"PAMP","tumor":"melanoma","sage":"discovery","pharma":"pharma","combo":"yes","model":"preclinical xeno"},{"id":10861,"name":10861,"title":"Imprime PGG, a soluble yeast \u03b2-glucan PAMP, in combination with Pembrolizumab induces infiltration and activation of both innate and adaptive immune cells within tumor sites in melanoma and triple-negative breast cancer (TNBC) patients","presenterFirst":"Mark","presenterLast":"Uhlik","keywords":"Immune response;Imprime PGG;melanoma;Triple negative breast cancer","target":"PAMP","tumor":"melanoma","sage":"target-tumor","pharma":"pharma","combo":"yes","model":"clinical"}]},{"id":"PARP1/2","name":"PARP1/2","presenterLast":"PARP1/2","children":[{"id":2325,"name":2325,"title":"Evaluation of niraparib in combination with anti-PD1/anti-PD-L1 in preclinical models","presenterFirst":"Sarah","presenterLast":"Wang","keywords":"Combination studies;Checkpoint;PARP;Combination therapy","target":"PARP1/2","tumor":"ovarian","sage":"discovery","pharma":"pharma","combo":"yes","model":"preclinical xeno"}]},{"id":"PD1/L1","name":"PD1/L1","presenterLast":"PD1/L1","children":[{"id":2082,"name":2082,"title":"Novel small-molecule inhibitor of PD1/PDL1 pathway demonstrated single agent and drug combo effectiveness in cancer immunotherapy","presenterFirst":"Yuguang","presenterLast":"Wang","keywords":"Immunotherapy;Small molecule PD1/PDL1 inhibitor;anti-CTLA4;Epacadostat","target":"PD1/L1","tumor":"colorectal","sage":"drug","pharma":"pharma","combo":"yes","model":"preclinical xeno"},{"id":3699,"name":3699,"title":"Novel, heterocyclic small molecule inhibitors of PD-1 and PD-L1 pathway","presenterFirst":"Sivanandhan","presenterLast":"Dhanalakshmi","keywords":"Immunomodulation;Small molecule inhibitor","target":"PD1/L1","tumor":"renal","sage":"drug","pharma":"pharma","combo":"no","model":"preclinical in vitro"}]},{"id":"PI3Kg","name":"PI3Kg","presenterLast":"PI3Kg","children":[{"id":6224,"name":6224,"title":"The role of MEN1611, a class I PI3-kinases (PI3Ks) inhibitor, in reprogramming the pro-tumoral inflammatory environment","presenterFirst":"Stefania","presenterLast":"Capano","keywords":"PI3K;Macrophages","target":"PI3Kg","tumor":"breast_colorectal","sage":"discovery","pharma":"pharma","combo":"no","model":"preclinical xeno"}]},{"id":"STAT3_IRS1/2","name":"STAT3_IRS1/2","presenterLast":"STAT3_IRS1/2","children":[{"id":6119,"name":6119,"title":"NT219, a novel dual inhibitor of STAT3 and IRS1/2, converts immuno-oncology resistant tumors to responders","presenterFirst":"Izhak","presenterLast":"Haviv","keywords":"Drug resistance;Immunomodulation;Combination therapy;Efficacy","target":"STAT3_IRS1/2","tumor":"multiple","sage":"drug","pharma":"pharma","combo":"yes","model":"preclinical xeno"}]},{"id":"STING","name":"STING","presenterLast":"STING","children":[{"id":4151,"name":4151,"title":"Preclinical characterization of GSK532, a novel STING agonist with potent anti-tumor activity","presenterFirst":"Jingsong","presenterLast":"Yang","keywords":"Cancer immunotherapy;Immunostimulation;Antigen presentation;Interferons","target":"STING","tumor":"colorectal","sage":"drug","pharma":"pharma","combo":"no","model":"preclinical xeno"},{"id":5025,"name":5025,"title":"Combining STING agonists with an anti-PD-1 antagonist results in marked antitumor activity in immune-excluded tumors","presenterFirst":"Samanthi","presenterLast":"Perera","keywords":"Immunotherapy;Innate immunity;Adoptive immunotherapy;Mouse models","target":"STING","tumor":"melanoma_colorectal","sage":"target-tumor","pharma":"pharma","combo":"yes","model":"preclinical xeno"},{"id":6327,"name":6327,"title":"Endogenous STING inhibition induces breast cancer cell death","presenterFirst":"Hery","presenterLast":"Ratsima","keywords":"Breast cancer;Drug resistance;DNA damage;Immunotherapy","target":"STING","tumor":"breast","sage":"discovery","pharma":"pharma","combo":"no","model":"preclinical xeno"},{"id":8244,"name":8244,"title":"Intratumoral activation of STING with a synthetic cyclic dinucleotide elicits antitumor CD8 T-cell immunity that effectively combines with checkpoint inhibitors","presenterFirst":"Sarah","presenterLast":"McWhirter","keywords":"Checkpoint;Cancer immunotherapy;Innate immunity;Tumor microenvironment","target":"STING","tumor":"NA","sage":"target-tumor","pharma":"pharma","combo":"yes","model":"preclinical xeno"}]},{"id":"TAM","name":"TAM","presenterLast":"TAM","children":[{"id":7410,"name":7410,"title":"Mechanistic and pharmacodynamic characterization of the immuno-oncological activity of RXDX-106, a novel TYRO3, AXL, and MER (TAM) inhibitor in clinical development","presenterFirst":"Amanda","presenterLast":"Albert","keywords":"Immunomodulation;Innate immunity;Tyrosine kinase inhibitor;Macrophages","target":"TAM","tumor":"NA","sage":"drug","pharma":"pharma","combo":"no","model":"preclinical xeno"}]},{"id":"TLR7","name":"TLR7","presenterLast":"TLR7","children":[{"id":2290,"name":2290,"title":"Novel intravenous injectable TLR7 agonist, DSP-0509, synergistically enhanced antitumor immune responses in combination with anti-PD-1 antibody","presenterFirst":"Yosuke","presenterLast":"Ota","keywords":"Combination therapy;TLR7;PD-1;memory T cell","target":"TLR7","tumor":"colorectal","sage":"drug","pharma":"pharma","combo":"yes","model":"preclinical xeno"}]},{"id":"TLR7/8","name":"TLR7/8","presenterLast":"TLR7/8","children":[{"id":2952,"name":2952,"title":"Identifying characteristics of orthotopic HCC mouse models to predict response to immunotherapy","presenterFirst":"Carina","presenterLast":"Hage","keywords":"Hepatocellular carcinoma;Immunotherapy;Mouse models;Combination therapy","target":"TLR7/8","tumor":"hcc","sage":"target-tumor","pharma":"pharma","combo":"yes","model":"preclinical xeno"},{"id":3077,"name":3077,"title":"NKTR-262: Prodrug pharmacokinetics in mice, rats, and dogs","presenterFirst":"Myong","presenterLast":"Lee","keywords":"Immunotherapy","target":"TLR7/8","tumor":"NA","sage":"drug","pharma":"pharma","combo":"no","model":"preclinical xeno"},{"id":6137,"name":6137,"title":"Intratumoral immunotherapy with TLR7/8 agonist MEDI9197 modulates the tumor microenvironment leading to enhanced activity when combined with other immunotherapies","presenterFirst":"Katharina","presenterLast":"Deschler","keywords":"Innate immunity;Checkpoint;T lymphocytes","target":"TLR7/8","tumor":"melanoma","sage":"drug","pharma":"pharma","combo":"yes","model":"preclinical xeno"},{"id":6912,"name":6912,"title":"Comprehensive antitumor immune activation by a novel TLR7/8 targeting agent NKTR-262 combined with CD122-biased immunostimulatory cytokine NKTR-214","presenterFirst":"Saul","presenterLast":"Kivimae","keywords":"Dendritic cells;Tumor immunity;Cancer immunotherapy;T cell","target":"TLR7/8","tumor":"NA","sage":"drug","pharma":"pharma","combo":"yes","model":"preclinical xeno"}]},{"id":"TLR8","name":"TLR8","presenterLast":"TLR8","children":[{"id":3285,"name":3285,"title":"Preclinical study of a novel TLR8 selective agonist for cancer immunotherapy","presenterFirst":"Yuxun","presenterLast":"Wang","keywords":"Cancer immunotherapy;Targeted therapy;Innate immunity;Drug discovery","target":"TLR8","tumor":"leukemia","sage":"target-tumor","pharma":"pharma","combo":"yes","model":"preclinical xeno"}]},{"id":"TLR9","name":"TLR9","presenterLast":"TLR9","children":[{"id":2544,"name":2544,"title":"TLR9 agonist SNA-induced innate and adaptive immune responses in tumor microenvironment enhance checkpoint inhibitor antitumor activity in mouse tumor models","presenterFirst":"SubbaRao","presenterLast":"Nallagatla","keywords":"Immunostimulation;Innate immunity;Checkpoint;Antitumor activity","target":"TLR9","tumor":"colorectal_lymphoma","sage":"drug","pharma":"pharma","combo":"yes","model":"preclinical xeno"},{"id":3070,"name":3070,"title":"Triple combination of IMO-2125, epacadostat and anti-PD-1 antibody demonstrates maximal antitumor efficacy and eradicates large established tumors in preclinical models","presenterFirst":"Daqing","presenterLast":"Wang","keywords":"Immunotherapy;Tumor microenvironment;Immunomodulation;Combination therapy","target":"TLR9","tumor":"colorectal","sage":"target-tumor","pharma":"pharma","combo":"yes","model":"preclinical xeno"}]},{"id":"TNIK","name":"TNIK","presenterLast":"TNIK","children":[{"id":455,"name":455,"title":"Traf2-and Nck-interacting kinase (TNIK) inhibitor, NCB-0846, suppresses TGF-\u03b21-induced epithelial-mesenchymal transition in lung cancer","presenterFirst":"Teppei","presenterLast":"Sugano","keywords":"EMT;TGF-beta;Metastasis;Therapeutics","target":"TNIK","tumor":"lung","sage":"drug","pharma":"pharma","combo":"no","model":"preclinical xeno"}]},{"id":"USP7","name":"USP7","presenterLast":"USP7","children":[{"id":3556,"name":3556,"title":"Discovery and optimization of potent and selective inhibitors of USP7 to enhance anti-tumor immunity and target tumor growth","presenterFirst":"Paul","presenterLast":"Kassner","keywords":"Tumor immunity;Regulatory T cell;Deubiquitinase inhibitor;p53","target":"USP7","tumor":"NA","sage":"drug","pharma":"pharma","combo":"yes","model":"preclinical in vitro"}]}]}
